Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation.

Zhang H, Freitas D, Kim HS, Fabijanic K, Li Z, Chen H, Mark MT, Molina H, Martin AB, Bojmar L, Fang J, Rampersaud S, Hoshino A, Matei I, Kenific CM, Nakajima M, Mutvei AP, Sansone P, Buehring W, Wang H, Jimenez JP, Cohen-Gould L, Paknejad N, Brendel M, Manova-Todorova K, Magalhães A, Ferreira JA, Osório H, Silva AM, Massey A, Cubillos-Ruiz JR, Galletti G, Giannakakou P, Cuervo AM, Blenis J, Schwartz R, Brady MS, Peinado H, Bromberg J, Matsui H, Reis CA, Lyden D.

Nat Cell Biol. 2018 Mar;20(3):332-343. doi: 10.1038/s41556-018-0040-4. Epub 2018 Feb 19.

PMID:
29459780
2.

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P; TAXYNERGY Investigators.

J Clin Oncol. 2017 Oct 1;35(28):3181-3188. doi: 10.1200/JCO.2017.72.4138. Epub 2017 Jun 20.

3.

Widespread Mitotic Bookmarking by Histone Marks and Transcription Factors in Pluripotent Stem Cells.

Liu Y, Pelham-Webb B, Di Giammartino DC, Li J, Kim D, Kita K, Saiz N, Garg V, Doane A, Giannakakou P, Hadjantonakis AK, Elemento O, Apostolou E.

Cell Rep. 2017 May 16;19(7):1283-1293. doi: 10.1016/j.celrep.2017.04.067.

4.

Using circulating tumor cells to advance precision medicine in prostate cancer.

Galletti G, Worroll D, Nanus DM, Giannakakou P.

J Cancer Metastasis Treat. 2017;3:190-205. doi: 10.20517/2394-4722.2017.45. Epub 2017 Sep 27.

5.

A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

Jing H, Hu J, He B, Negrón Abril YL, Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T, Giannakakou P, Weiss RS, Lin H.

Cancer Cell. 2016 May 9;29(5):767-768. doi: 10.1016/j.ccell.2016.04.005. Epub 2016 May 9. No abstract available.

6.

A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

Jing H, Hu J, He B, Negrón Abril YL, Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T, Giannakakou P, Weiss RS, Lin H.

Cancer Cell. 2016 Apr 11;29(4):607. doi: 10.1016/j.ccell.2016.03.011. No abstract available.

7.

A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

Jing H, Hu J, He B, Negrón Abril YL, Stupinski J, Weiser K, Carbonaro M, Chiang YL, Southard T, Giannakakou P, Weiss RS, Lin H.

Cancer Cell. 2016 Mar 14;29(3):297-310. doi: 10.1016/j.ccell.2016.02.007. Erratum in: Cancer Cell. 2016 Apr 11;29(4):607. Giannakakou, Paraszkevi [corrected to Giannakakou, Paraskevi]. Cancer Cell. 2016 May 9;29(5):767-768.

8.

CANCER. Cancer therapies that are gone with the Wnt.

Nanus DM, Giannakakou P.

Science. 2015 Sep 18;349(6254):1283-4. doi: 10.1126/science.aad2448. No abstract available.

PMID:
26383936
9.

Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.

Diamond E, Molina AM, Carbonaro M, Akhtar NH, Giannakakou P, Tagawa ST, Nanus DM.

Crit Rev Oncol Hematol. 2015 Dec;96(3):518-26. doi: 10.1016/j.critrevonc.2015.08.007. Epub 2015 Aug 13. Review.

PMID:
26321263
10.

β-1 tubulin R307H SNP alters microtubule dynamics and affects severity of a hereditary thrombocytopenia.

Basciano PA, Matakas J, Pecci A, Civaschi E, Cagioni C, Bompiani N, Burger P, Christos P, Snyder JP, Bussel J, Balduini CL, Giannakakou P, Noris P.

J Thromb Haemost. 2015 Apr;13(4):651-9. doi: 10.1111/jth.12824. Epub 2015 Jan 22.

11.

ERG induces taxane resistance in castration-resistant prostate cancer.

Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS.

Nat Commun. 2014 Nov 25;5:5548. doi: 10.1038/ncomms6548.

12.

Decade in review-funding in cancer research: National Cancer Institute awards-a work in progress.

Fojo T, Giannakakou P.

Nat Rev Clin Oncol. 2014 Nov;11(11):634-6. doi: 10.1038/nrclinonc.2014.173. Epub 2014 Oct 14. No abstract available.

PMID:
25311348
13.

RABbing cancer the wrong way.

Khade PK, Giannakakou P.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):11230-1. doi: 10.1073/pnas.1410788111. Epub 2014 Jul 22. No abstract available.

14.

NAD+ and SIRT3 control microtubule dynamics and reduce susceptibility to antimicrotubule agents.

Harkcom WT, Ghosh AK, Sung MS, Matov A, Brown KD, Giannakakou P, Jaffrey SR.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):E2443-52. doi: 10.1073/pnas.1404269111. Epub 2014 Jun 2.

15.

Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.

Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM.

Mol Diagn Ther. 2014 Aug;18(4):389-402. doi: 10.1007/s40291-014-0101-8.

16.

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P.

Cancer Res. 2014 Apr 15;74(8):2270-2282. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20.

17.

Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.

Gakhar G, Navarro VN, Jurish M, Lee GY, Tagawa ST, Akhtar NH, Seandel M, Geng Y, Liu H, Bander NH, Giannakakou P, Christos PJ, King MR, Nanus DM.

PLoS One. 2013 Dec 27;8(12):e85143. doi: 10.1371/journal.pone.0085143. eCollection 2013.

18.

Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.

Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, Kirby BJ, Giannakakou P.

Lab Chip. 2014 Jan 7;14(1):147-56. doi: 10.1039/c3lc51039e. Epub 2013 Nov 7.

19.

BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.

Sung M, Giannakakou P.

Oncogene. 2014 Mar 13;33(11):1418-28. doi: 10.1038/onc.2013.85. Epub 2013 Mar 25.

20.

The beta 1 tubulin R307H single nucleotide polymorphism is associated with treatment failures in immune thrombocytopenia (ITP).

Basciano PA, Bussel J, Hafeez Z, Christos PJ, Giannakakou P.

Br J Haematol. 2013 Jan;160(2):237-43. doi: 10.1111/bjh.12124. Epub 2012 Nov 15.

21.

Isolation and characterization of circulating tumor cells in prostate cancer.

Diamond E, Lee GY, Akhtar NH, Kirby BJ, Giannakakou P, Tagawa ST, Nanus DM.

Front Oncol. 2012 Oct 11;2:131. doi: 10.3389/fonc.2012.00131. eCollection 2012.

22.

Integrating image analysis algorithms in a web interface for the quantification of microtubule dynamics.

Kong KY, Marcus AI, Giannakakou P, Wang MD.

Int J Comput Biol Drug Des. 2012;5(3-4):298-313. doi: 10.1504/IJCBDD.2012.049211. Epub 2012 Sep 24.

PMID:
23013655
23.

Androgen receptor on the move: boarding the microtubule expressway to the nucleus.

Thadani-Mulero M, Nanus DM, Giannakakou P.

Cancer Res. 2012 Sep 15;72(18):4611-5. doi: 10.1158/0008-5472.CAN-12-0783. Review.

24.

Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.

Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Navarro VN, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.

PLoS One. 2012;7(4):e35976. doi: 10.1371/journal.pone.0035976. Epub 2012 Apr 27. Erratum in: PLoS One. 2012;7(7): doi/10.1371/annotation/9d3d22ed-dc5a-4484-9254-1584864f4aac.

25.

Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy.

Carbonaro M, Escuin D, O'Brate A, Thadani-Mulero M, Giannakakou P.

J Biol Chem. 2012 Apr 6;287(15):11859-69. doi: 10.1074/jbc.M112.345587. Epub 2012 Feb 24.

26.

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.

Cancer Res. 2011 Sep 15;71(18):6019-29. doi: 10.1158/0008-5472.CAN-11-1417. Epub 2011 Jul 28.

27.

A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.

Wang X, Li J, Wang Y, Koenig L, Gjyrezi A, Giannakakou P, Shin EH, Tighiouart M, Chen ZG, Nie S, Shin DM.

ACS Nano. 2011 Aug 23;5(8):6184-94. doi: 10.1021/nn200739q. Epub 2011 Jul 11.

28.

Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.

Kanakkanthara A, Wilmes A, O'Brate A, Escuin D, Chan A, Gjyrezi A, Crawford J, Rawson P, Kivell B, Northcote PT, Hamel E, Giannakakou P, Miller JH.

Mol Cancer Ther. 2011 Aug;10(8):1419-29. doi: 10.1158/1535-7163.MCT-10-1057. Epub 2011 Jun 8.

29.

Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.

Kauh J, Chanel-Vos C, Escuin D, Fanucchi MP, Harvey RD, Saba N, Shin DM, Gal A, Pan L, Kutner M, Ramalingam SS, Bender L, Marcus A, Giannakakou P, Khuri FR.

Cancer. 2011 Sep 1;117(17):4049-59. doi: 10.1002/cncr.26004. Epub 2011 Mar 1.

30.

Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression.

Carbonaro M, O'Brate A, Giannakakou P.

J Cell Biol. 2011 Jan 10;192(1):83-99. doi: 10.1083/jcb.201004145.

31.

Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.

Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM.

Urol Oncol. 2011 Nov-Dec;29(6):676-81. doi: 10.1016/j.urolonc.2009.12.023. Epub 2010 May 7.

PMID:
20451413
32.

CENP-E checks in microtubule-drug resistance.

Chanel-Vos C, Giannakakou P.

Cell Cycle. 2010 Apr 15;9(8):1456. Epub 2010 Apr 15. No abstract available.

PMID:
20421712
33.

Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.

Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ.

Lab Chip. 2010 Jan 7;10(1):27-9. doi: 10.1039/b917959c. Epub 2009 Nov 16.

34.

The hematopoietic-specific beta1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression.

Escuin D, Burke PA, McMahon-Tobin G, Hembrough T, Wang Y, Alcaraz AA, Leandro-García LJ, Rodríguez-Antona C, Snyder JP, Lavallee TM, Giannakakou P.

Cell Cycle. 2009 Dec;8(23):3914-24. Epub 2009 Dec 16.

PMID:
19901556
35.

HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors.

Wang X, Li J, Wang Y, Cho KJ, Kim G, Gjyrezi A, Koenig L, Giannakakou P, Shin HJ, Tighiouart M, Nie S, Chen ZG, Shin DM.

ACS Nano. 2009 Oct 27;3(10):3165-74. doi: 10.1021/nn900649v.

36.

The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.

Zhou J, Vos CC, Gjyrezi A, Yoshida M, Khuri FR, Tamanoi F, Giannakakou P.

J Biol Chem. 2009 Apr 10;284(15):9648-55. doi: 10.1074/jbc.M808708200. Epub 2009 Feb 18.

37.

EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.

Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E, Giannakakou P.

Cell Cycle. 2008 Aug;7(15):2409-17. Epub 2008 Jun 9.

38.
39.

Automatic microtubule tracking for QD-based in vivo cell imaging and drug efficacy study.

Kong KY, Marcus AI, Hong JY, Giannakakou P, Wang MD.

Conf Proc IEEE Eng Med Biol Soc. 2006;1:3321-4.

PMID:
17947021
40.

Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function.

Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI.

Mol Cancer Ther. 2007 Apr;6(4):1317-28.

41.

Computer assisted analysis of microtubule dynamics in living cells.

Yin Kong K, Marcus A, Young Hong J, Giannakakou P, Wang M.

Conf Proc IEEE Eng Med Biol Soc. 2005;4:3982-5.

PMID:
17281104
42.

Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues.

Ganesh T, Yang C, Norris A, Glass T, Bane S, Ravindra R, Banerjee A, Metaferia B, Thomas SL, Giannakakou P, Alcaraz AA, Lakdawala AS, Snyder JP, Kingston DG.

J Med Chem. 2007 Feb 22;50(4):713-25. Epub 2007 Jan 31.

43.

Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model.

Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW, Lavallee TM, Giannakakou P, Van Meir EG, Shim H.

Cancer Res. 2006 Dec 15;66(24):11991-7.

44.

Farnesyltransferase inhibitors reverse taxane resistance.

Marcus AI, O'Brate AM, Buey RM, Zhou J, Thomas S, Khuri FR, Andreu JM, Díaz F, Giannakakou P.

Cancer Res. 2006 Sep 1;66(17):8838-46.

45.

Molecular design and chemical synthesis of a highly potent epothilone.

Nicolaou KC, Pratt BA, Arseniyadis S, Wartmann M, O'Brate A, Giannakakou P.

ChemMedChem. 2006 Jan;1(1):41-4. No abstract available.

PMID:
16892332
46.

Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.

Buey RM, Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I, Mooberry S, Andreu JM, Díaz JF.

Chem Biol. 2005 Dec;12(12):1269-79.

47.
48.

Discovery of a biologically active thiostrepton fragment.

Nicolaou KC, Zak M, Rahimipour S, Estrada AA, Lee SH, O'Brate A, Giannakakou P, Ghadiri MR.

J Am Chem Soc. 2005 Nov 2;127(43):15042-4.

PMID:
16248640
49.

beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.

Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW Jr.

Cancer Res. 2005 Oct 15;65(20):9406-14.

Supplemental Content

Loading ...
Support Center